PMI Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -26.16%, SMA50 -35.11%, SMA200 -72.53%). The stock’s 14-day RSI is 30.23 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -91.59% below its high and over 1.77% above its low. Average 10-day trading volume of 255.63 thousand shares is below the 3-month average of 796.11 thousand, indicating normal recent market interest.

Picard Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.39. This means the shares are trading below this model’s fair value.

Picard Medical, Inc. (AMEX:PMI) closed at $0.69 USD, losing -$0.16 (-18.44%) from the previous close of $0.85. The stock is currently trading near its 52-week low $0.69 and $13.68. With a market capitalization of about $1.08 billion, Picard Medical, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~4.56). Key stats such as the average daily volume over the past year has been around 770.10 thousand shares, volume is running light vs its 52-week average. Headquartered in Tucson, AZ, Picard Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Patrick N. J. Schnegelsberg, the company employs approximately 75 people and listed since August 22, 2025. Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.

currently trading near 52-week highs band. Valuation shows Picard Medical, Inc. trading at a premium to the broader market with a P/E of -1.91.

Our AI price prediction model suggests that Picard Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Picard Medical, Inc. trades at a P/E ratio of -1.91, slightly below the S&P 500 average, with a price-to-sales ratio of 227.02 and a price-to-book ratio of 14.0 reflecting a rich premium to book value. The P/FCF stands at -71.65, also below market averages. Compared to sector medians, Picard Medical, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.